REFERENCES

1. Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21:5888.

2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.

3. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283-98.

4. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.

5. Battistella S, D’Arcangelo F, Grasso M, et al. Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management. Clin Mol Hepatol. 2023;29:S286-301.

6. Daher D, Dahan KSE, Singal AG. Non-alcoholic fatty liver disease-related hepatocellular carcinoma. J Liver Cancer. 2023;23:127-42.

7. Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119:1787-98.

8. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.

9. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.

10. Lancet Gastroenterology Hepatology. Redefining non-alcoholic fatty liver disease: what’s in a name?. Lancet Gastroenterol Hepatol. 2020;5:419.

11. Premkumar M, Anand AC. Lean fatty liver disease: through thick and thin. J Clin Exp Hepatol. 2021;11:523-7.

12. Chen L. From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: controversy and consensus. World J Hepatol. 2023;15:1253-7.

13. Fouad Y. Metabolic-associated fatty liver disease: new nomenclature and approach with hot debate. World J Hepatol. 2023;15:123-8.

14. Duseja A, De A, Mehta M, et al. Patients with metabolic-dysfunction associated fatty liver disease (MAFLD) without associated etiologies and non-MAFLD non-alcoholic fatty liver disease (NAFLD) have similar liver disease severity - data from Indian Consortium on NAFLD (ICON-D). J Clin Exp Hepatol. 2022;12:S73-4.

15. Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD?. Clin Mol Hepatol. 2023;29:S17-31.

16. Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1:329-41.

17. Singh SP, Anirvan P, Reddy KR, et al. Non-alcoholic fatty liver disease: not time for an obituary just yet!. J Hepatol. 2021;74:972-4.

18. Duseja A, Taneja S. Changing nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease - not only premature but also confusing. J Clin Exp Hepatol. 2021;11:278-9.

19. Singh SP, Anirvan P, Butt AS, et al. NAFLD vs MAFLD: South Asian NAFLD patients don’t favor name change. Euroasian J Hepatogastroenterol. 2022;12:S1-4.

20. Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73:1194-8.

21. Society for Paediatric Gastroenterology Hepatology (ESPGHAN) and European Association for the Study of the Liver (EASL), on behalf of co-authors. Electronic address: j.p.mann@bham.ac.uk; European Society for Paediatric Gastroenterology Hepatology (ESPGHAN) and European Association for the Study of the Liver (EASL), on behalf of co-authors. Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease. Lancet Gastroenterol Hepatol. 2023;8:598-600.

22. Singh SP, Sudhamshu KC, Anirvan P, Shrestha A, Mahtab MA. Nonalcoholic fatty liver disease vs metabolic-associated fatty liver disease vs metabolic dysfunction-associated steatotic liver disease: what’s in the name?. Euroasian J Hepatogastroenterol. 2024;14:1-4.

23. García-Compeán D, Jiménez-Rodríguez AR. NAFLD vs MAFLD. The evidence-based debate has come. Time to change? Ann Hepatol. 2022;27:100765.

24. Anand AC. MASLD, MLA pesarattu and other developments. J Clin Exp Hepatol. 2025;15:102465.

25. Schuckit MA, Clarke DF, Smith TL, Mendoza LA. Characteristics associated with denial of problem drinking among two generations of individuals with alcohol use disorders. Drug Alcohol Depend. 2020;217:108274.

26. Portincasa P. NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. Intern Emerg Med. 2023;18:993-1006.

27. Arab JP, Díaz LA, Rehm J, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease. J Hepatol. 2025;82:744-56.

28. Israelsen M, Torp N, Johansen S, et al; GALAXY consortium. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024;9:218-28.